BRIEF published on 04/28/2025 at 09:13, 1 year 1 month ago MVISE AG annonce un premier trimestre 2025 solide EBITDA Performance Financière Prévisions De Croissance MVISE AG Résultats Du Premier Trimestre 2025
BRIEF published on 04/28/2025 at 09:13, 1 year 1 month ago MVISE AG Reports Robust First Quarter in 2025 EBITDA Financial Performance Growth Forecast MVISE AG Q1 2025 Results
PRESS RELEASE published on 04/28/2025 at 09:08, 1 year 1 month ago mVISE AG: strong first quarter of 2025 mVISE AG reports a strong first quarter of 2025 with EUR 0.31 million EBITDA and a 17.2% margin, aiming for +15% EBITDA growth for the year. CEO Ralf Thomas highlights successful market entry despite macroeconomic conditions EBITDA Growth Forecast First Quarter 2025 MVISE AG Ralf Thomas
BRIEF published on 03/27/2025 at 10:07, 1 year 2 months ago NuWays recommande d'acheter mVISE AG Rentabilité Recommandation D'achat Objectif De Prix NuWays MVISE AG
BRIEF published on 03/27/2025 at 10:07, 1 year 2 months ago NuWays Issues 'Buy' Recommendation for mVISE AG Profitability Buy Recommendation Price Target NuWays MVISE AG
PRESS RELEASE published on 03/27/2025 at 10:02, 1 year 2 months ago Research update from NuWays available - 'Buy' recommendation and price target of EUR 1.30 mVISE AG receives 'Buy' recommendation with EUR 1.30 price target in research update from NuWays AG. Strong increase in profitability and successful strategic realignment highlighted Profitability NuWays AG Research Update Strategic Realignment MVISE AG
BRIEF published on 03/26/2025 at 09:07, 1 year 3 months ago MVISE AG Shows Profitability Amid Sales Decline Buy Recommendation EBITDA Growth FY24 Results MVISE AG Restructuring Impact
BRIEF published on 03/26/2025 at 09:07, 1 year 3 months ago MVISE AG affiche une rentabilité malgré une baisse des ventes Recommandation D'achat Croissance De L'EBITDA Résultats De L'exercice 2024 MVISE AG Impact De La Restructuration
PRESS RELEASE published on 03/26/2025 at 09:02, 1 year 3 months ago Original-Research: mVISE AG (von NuWays AG): BUY mVISE AG releases FY24 figures showing increased profitability with sales decline but EBITDA improvement. New guidance targets 15% yoy EBITDA increase for FY25 Profitability Sales Decline Guidance MVISE AG FY24 Figures
BRIEF published on 02/04/2025 at 07:47, 1 year 4 months ago MVISE AG bénéficie d'un important allègement de sa dette Financement Soutien Financier MVISE AG Annulation De Dette Revenus Extraordinaires
Published on 06/26/2026 at 14:05, 2 hours 56 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 3 hours 1 minute ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 4 hours 1 minute ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 4 hours 16 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 15:30, 1 hour 31 minutes ago JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 1 hour 37 minutes ago Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 06/26/2026 at 15:23, 1 hour 38 minutes ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 1 hour 39 minutes ago Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 06/26/2026 at 07:00, 10 hours 1 minute ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 10 hours 1 minute ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
